GH Research PLC (GHRS) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Dublin, Ireland. The current CEO is Velichka Valcheva.
GHRS has IPO date of 2021-06-25, 50 full-time employees, listed on the NASDAQ Global Market, a market capitalization of $1.05B.
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.
